PDA Comments ICH Q10; Pharmaceutical Quality System October Suggested Revision

Similar documents
Q10 PHARMACEUTICAL QUALITY SYSTEM

Textvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf

Pharmaceutical Quality System (PQS)

22 January Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852

FDA s Draft Guidance Request for Quality Metrics: What All Drug and Biologics Manufacturers Need to Know June 2017

RE: Draft Annex 2: Manufacture of Biological Medicinal Products for Human Use

The long anticipated draft of the FDA s

WHO DRAFT PHARMACEUTICAL DEVELOPMENT FOR MULTISOURCE (GENERIC) PHARMACEUTICAL PRODUCTS

European Medicines Agency Quality Working Party, London

PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT

IAASB Main Agenda (March 2016) Agenda Item. Initial Discussion on the IAASB s Future Project Related to ISA 315 (Revised) 1

Kim Christiansen, Danish Standards 1

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4

International Pharmaceutical Excipients Council Of The Americas

EFFECTIVE MANAGEMENT OF THE PROCESS VALIDATION LIFECYCLE VALIDATION MASTER PLAN DEVELOPMENT

Quality Risk Management

Enabling Improvement through the Product Lifecycle: Change Management within a PQS

Overview of comments received on 'Draft Guideline on the chemistry of active substances (veterinary) (EMA/CVMP/QWP/49477/2017)

CGEIT QAE ITEM DEVELOPMENT GUIDE

Re: Docket No. FDA-2015-D-1246: Draft Guidance on Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment

SUBMISSION OF COMMENTS ON GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS - EMEA/CHMP/BWP/398498/2005

FDA Quality Metrics, Data Integrity and Application of Statistics Throughout Process Validation in a Global Economy

Subject: EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 15: Qualification and Validation

COMMENTS FROM EUROPABIO GENERAL COMMENTS

EU and FDA GMP Regulations: Overview and Comparison

Top Annual 483 Observations: The Cycle of Quality June 2017 Presented by: Susan Schniepp

API Comments on OSHA Guidance Document on Process Safety Management Guidelines for Small Business Compliance September 29, 2016

ICH Q12 Perspectives: The Robust PQS

Strategies to Revise Quality Policy and Quality Objectives. Eileen Cortes February 22, 2017

Overview of comments received on 'Draft Guideline on manufacture of the finished dosage form'

Proposed International Standard on Auditing 315 (Revised)

Process Capability and relationship to Quality management

Need to clarify the relationship of the proposed Framework to the IAASB s authoritative literature

IAASB CAG Public Session (March 2016) Agenda Item. Initial Discussion on the IAASB s Future Project Related to ISA 315 (Revised) 1

For your consideration, below is a summary of our key concerns. Additional detailed discussion is included in the attached.

Regulatory Update. Greg McGurk, GMP Manager (acting) GMP Conference. 7 February 2017 Dublin

Management Responsibilities Comparative Table

December 12, Dockets Management Staff (HFA 305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852

Synopsis: FDA Process Validation Guidance

Association of Accounting Technicians response to the IAESB Exposure Draft on Continuing Professional Development

P. 1. Identify the Differences between ISO9001:2000 與 ISO9001:2008 ISO9001:2008 ISO9001:2000 版本的異同. 5 January 2009 ISO 9000 SERIES

European Union (EU) Regulatory Trends in GMP. Clive Brading Tianjin, China September 23, 2009

ICH Quality Implementation Working Group POINTS TO CONSIDER

QbD Concepts Applied to Qualification and Transfer of Analytical Methods

RESEARCH SUPPORT SERVICES FRAMEWORK. Streamlining the management and governance of R&D studies in the NHS

IAASB Main Agenda (September 2017)

CAPA Management: Best Practices and FDA QSR Mandate WHITE PAPER. ComplianceQuest In-Depth Analysis and Review

PROCESS VALIDATION Jaap Koster. Pharmaceutical Consultancy Services, All rights reserved.

August 1, A. Overall Comments; B. Request for Specific Comments; and

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

Re: Information System Services (formerly Information Systems Design, Implementation, or Integration)

Pharmacovigilance System Master file

Draft Guidance for Industry Development and Use of Risk Minimization Action Plans

Quality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers

Draft Guidelines on the Formalised Risk Assessment for Ascertaining the Appropriate GMG for Excipients of Medicinal Products for Human Use

Guidance for Industry

The Impact of Quality Culture on Quality Risk Management. FDA Perspective on Quality Culture; how it Impacts Risk Management

Lifecycle Product Quality Risk Management

ISO Introduction and Background

Inspection. Implementation of ICH Q8, Q9, Q10

THE NEW QUALITY PARADIGM OPPORTUNITIES AND EXPECTATIONS IN ICH Q8 Q9 Q10 Q11 DR. FRITZ ERNI

Quality Systems. Indian Pharmaceutical Alliance. Advanced GMP Workshops 2017

January 19, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

ICH Q10/WHO TRS A Regulatory Perspective

Quality Risk Management. of the GDP Supply Chain. Dr Cormac Dalton Inspector. Crowne Plaza Hotel, 25/2/2010. Date 22-Feb-10 Slide 1

IAASB Main Agenda Page Agenda Item

LIFE SCIENCE BENCHMARKING STUDY. Trends and Best Practices Based on Our Work with the US FDA and Over 250 Companies

Post market Surveillance ISO EU Medical Device Regulation

ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER TUUSULA FINLAND. Timo Kuosmanen STERIS Finn-Aqua

REVISED CORPORATE GOVERNANCE PRINCIPLES FOR BANKS (CONSULTATION PAPER) ISSUED BY THE BASEL COMMITTEE ON BANKING SUPERVISION

ICH Q8/Q8(R)

Re: Proposed Statement on Standards for Attestation Engagements, Attestation Standards: Clarification and Recodification

Quality Manual ISO 9001:2015 Quality Management System

Exposure draft on Improving the Clarity of IAASB Standards

<Full Name> Quality Manual. Conforms to ISO 9001:2015. Revision Date Record of Changes Approved By

FDA Draft Guidance for Industry Contract Manufacturing Arrangements for Drugs: Quality Agreements (May 2013) Pfizer Comments General Comments:

Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs)

CGEIT ITEM DEVELOPMENT GUIDE

On behalf of the PHSS Pharmaceutical and Healthcare Sciences Society (UK).

Impact of EU GMPs on Australian GMP. Trevor Schoerie PharmOut

Checklist for ISO14001:2004 (compared with 14001:1996) Standard Clause/Section

9001:2015, ISO 14001:2015 & ISO

PATHWAYS TO IMPROVE YOUR COMPANY S QUALITY CULTURE

Provläsningsexemplar / Preview. Third edition

G4 DEVELOPMENT. Document 2 of 12 Statistics: Quantitative Online Feedback. Second G4 Public Comment Period: Submissions.

Submission of comments on Guideline on Similar Biological Medicinal Products (CHMP/437/04 Rev1)

October 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

Document: ISO/TC 176/SC 2/N 730. Our ref

Ref: Federal Participation in the Development and Use of Voluntary Consensus Standards and in Conformity Assessment Activities.

Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (COM) COURSE DESCRIPTION

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice

A response to PRA s consultation paper CP26/17 Model risk management principles for stress testing

October 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

Since Annex 15 is not intended to cover APIs therefore the reference to ICH Q 11 does not make sense. (see comment 1) Expert Group May 2014

DATA INTEGRITY INSPECTION PERSPECTIVES

Safety risk based surveillance provisions

Regulation Redesign Simplifying Rules for City Building. Fall 2018

Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

Effective application of Risk Management techniques to Drug Safety: a pragmatic approach

Transcription:

PDA s ICH Q10; Pharmaceutical Quality System October 2007 Section Line 1.1 54 The inspectional impact of the optional nature of Q10 beyond what is required by current GMP can be further clarified. 1.1 After line 62 This paragraph provides an opportunity to strengthen the understanding of the relationship between ICH Q8, Q9, and Q10. 1.2 73 Novel excipient development is not required for all products 1.2 79 Given site transfers can and frequently do occur during development this section should include that possibility. 1.4 107-108 In reference to the sentence "When implemented, the effectiveness of the pharmaceutical quality system can normally be confirmed during a regulatory inspection at the manufacturing site.". Regulatory inspections are only one measure to provide assurance that a firm's pharmaceutical quality system is effective. 1.5 120 The term "control" is more appropriate than the term "capability". Modify the sentence beginning with Consequently, the content of ICH Q10 by adding at the end and not subject to review in the course of routine inspections. Add the following sentence at the end of the paragraph. "In combination with ICH Q8 and Q9, ICH Q10 will enable a desired state of drug development and product and process quality while reducing the barriers to continual improvement." Add where applicable after the words novel excipient development and remove the ";" Add as the first bullet "Site transfers during development;". Additional measures to provide evidence of quality system effectiveness, such as annual product/process reviews, quality system reviews, data on complaints and recalls, etc. should also be listed. Replace the phrase "thereby providing assurance of continued suitability and capability of processes with "thereby providing assurance of continued suitability October 9, 2007 Page 1 of 6

Section Line 1.5 121 Quality risk management is also a valuable tool for the ongoing evaluation of a monitoring and control system. 1.5 126-127 Quality risk management is one tool to facilitate the identification and prioritization of areas for improvement. 1.6 144 Quality risk management also includes scientific evaluation. 1.7 150 Roles and responsibilities as well as decision making processes are also critical elements to a pharmaceutical quality system. 1.7 153 Recognition of the state of product knowledge would strengthen point 1.7 ii). 1.7 166-167 A pharmaceutical quality system should include an evaluation of the effectiveness of the quality systems. 1.7 168 In some companies key performance indicators are financial indicators. 1.8 177-178 The sentence "Identification of the processes within the pharmaceutical quality system, as well as their sequences, linkages, and interdependencies." is too prescriptive and could lead to confusion and debate. 2.1 192 It is important to not only monitor but to monitor the effectiveness of the pharmaceutical quality system. and control of processes". Change the phrase "establishing the monitoring and control system" to "establishing and evaluating the monitoring and control system". Change the sentence "Quality risk management can be useful to identify and prioritize areas for improvement." to "Quality risk management as well as feedback systems such as Corrective Action/Preventive Action (CAPA) are useful tools for identifying and prioritizing areas for improvement." After the words "identifying" add ", scientifically evaluating,". Add a second sentence to 1.7 i) "Additionally, responsibilities as well as decision making processes should be defined clearly." After the word "goals" add "and product knowledge". After the words "Section 3" add "and pharmaceutical quality system effectiveness, as described in Section 4." Replace the phrase "key performance indicators" with "performance metrics". Replace the phrase "Identification of the processes within the pharmaceutical quality system, as well as their sequences, linkages, and interdependencies." with the phrase "A description of the quality system's organizing principles." Add before the word "pharmaceutical" the words "effectiveness of the". October 9, 2007 Page 2 of 6

Section Line 2.1 194 It is important to not only monitor but to monitor the effectiveness of the pharmaceutical quality system. 2.1 199 The definition of decision making processes is also an important management responsibility. 2.1 205 Management should approve and implement needed changes as well as advocate continual improvement. 2.2 208-209 Senior management should ensure that a quality policy is established. Senior as well as all levels of management should endorse, enable and be advocates of quality policy. 2.2 210 Meeting regulation is a requirement, not an expectation. 2.3 221-222 The interpretation of a "company's strategic plans" will vary greatly across the diversity of companies to which this document applies. Therefore, alternative wording is suggested. 2.3 225 In some companies key performance indicators are financial indicators. 2.4 240-242 Simplifying the wording of "Communication processes should ensure the escalation of certain product quality and pharmaceutical quality system issues to appropriate levels of Add after the word "implementation" the words "and effectiveness". Add after the word "interactions" the words" and decision making processes". After the word "improvement" add the phrase "and approve and implement needed product and process changes". Replace the sentence "Senior management should establish a quality policy that describes the overall intentions and direction of the company related to quality." with "Senior management should ensure that a quality policy that describes the overall intentions and direction of the company related to quality is established. All levels of management, including senior management, should endorse, enable and be advocates for the quality policy. " Replace the words "an expectation" with "the requirement". Replace the sentence "Quality objectives should align with the company's strategic plans and be consistent with the quality policy." with "Quality objectives should align with a company's corporate strategy and direction and be consistent with the quality policy." Replace the phrase "key performance indicators" with "performance metrics". Replace with the sentence "Communications processes should ensure the appropriate and timely escalation of product quality and pharmaceutical quality system issues." October 9, 2007 Page 3 of 6

Section Line management in a timely manner." can enhance the clarity and intent of the sentence, 2.7 253 The word "normally" could lead to confusion and debate. 3.1 298 It is important to not only identify improvement opportunities but to implement them as well. 3.2 319 The term "feed forward" is not commonly used terminology and may not be understood. Table I 336-337 Alternative wording is offered to this table as well as subsequent tables to clarify or enhance the content; these suggestions are labeled henceforth--table wording suggestion. Replace the words "Normally under" with "Unless otherwise stipulated in". Add after the word "identified" the words "and implemented". Define the term "feed forward". Replace the sentence "Quality risk management and monitoring conducted throughout development can be used to establish a control strategy for manufacturing." with "Design space knowledge generated and product and process monitoring conducted throughout development can be used to establish a control strategy for manufacturing." Table I 336-337 Table wording suggestion In the Development column replace the word "Monitoring" with the words "Knowledge obtained". Table I 336-337 Table wording suggestion In the Technology Transfer column replace the words "Monitoring of" with the words "Knowledge obtained during". Table II 350-351 The term "feed forward" is not commonly used terminology and may not be understood. 3.2 352-386 The section on change management can be improved and clarified. Simplified and streamlined wording is proposed In the Technology Transfer column define the term "feed forward". Modify current section (2) to add after "evaluated" the words "and justified" plus add a sentence after the first sentence of section (2) "The level of effort and complexity of the evaluation should be commensurate with the level of risk." In current section (5) add before the words "submission/approval" the additional word "notification/submission/approval". Delete sections (1) and (3), reducing the sections to three. October 9, 2007 Page 4 of 6

Section Line Table III 389-390 Table wording suggestion. In the Technology Transfer column, modify the sentence "The change management system should provide management and documentation of adjustments made to the process during technology transfer activities." to "The change management system should provide justification, management, and documentation of adjustments made to the process during technology transfer activities." 3.2 399 The management review should also include a review of the commitments made. After the introductory words "The results of" add the words "and the commitments made to". 3.2 409-413 The examples of appropriate action are not lettered appropriately and could lead to confusion. End the sentence after the word "action" and change to "actions.". Delete examples lettered (d) through (f). 4.1 426 Enhance the concept of management expectations. 4.1 428 In some companies key performance indicators are financial indicators 4.1 430 Enhance the concepts of effectiveness assessment by adding the concept of trending. 4.1 After Risk management is an important management Line 433 review item. 4.2 440 The intent of including Section 4.2.iii could be clarified. Enhance the introductory phrase "The review should include:" to add "The review should reinforce management's expectations to continually improve the pharmaceutical quality system and should include:" Delete the words "key performance indicators" and replace with "performance metrics". Add after the word "processes" the words "and trends" Add an additional item "(4) Risk assessments and control and remediation plans." Change the wording to Changes in business strategies and objectives which could impact a firm s quality policy. 4.3 447-448 Strengthen management's expectations. Begin the sentence with the words "Documentation and". After the word "results" add "and expectations". Change the words "senior management" to "appropriate levels of management". October 9, 2007 Page 5 of 6

Section Annex 1 Line 529-536 This annex could be clarified and improved by expanding on the Note. Revise the Note section by replacing the current text with the following: Firms who have demonstrated successful implementation of a Pharmaceutical Quality System and risk management program may be considered for flexible regulatory approaches. The following table reflects some examples of how these flexible regulatory approaches might occur. Initially, the degree and type of flexible regulatory approach would be based on the laws and regulations in place within each of the ICH regions. The ultimate goal would be to achieve a universal framework to providing flexible regulatory approaches. ICH Q10 Grid final.doc 10/9/07 October 9, 2007 Page 6 of 6